AmeriCann /
Our News
ACAN Hires Respected Greenhouse Scientist
0
Dr. Brian Corr named Director of Horticultural Science and Operations
DENVER, CO / May 4, 2017 / AmeriCann, Inc. (OTCQX: ACAN), an Agricultural Technology company that is developing sustainable, state-of-the-art medical cannabis cultivation properties, announced the hiring of Dr. Brian Corr as Director of Horticultural Science and Operations.
Dr. Brian A. Corr, a noted expert in controlled-environment horticulture, is a 40-year veteran in the traditional horticulture industry with companies such as Ball Horticulture and Syngenta (NYSE: SYT which has a $43 billion market capitalization). Dr. Corr will lead AmeriCann’s management services division.
“AmeriCann believes that for cannabis to reach its full potential as a medicine it requires the best facilities and operations,” stated AmeriCann CEO Tim Keogh. “Dr. Corr provides the best of two worlds – the science of traditional horticulture with the specific needs of cannabis cultivation. ”
Dr. Corr stated, “AmeriCann and I share a vision for the efficient and scientific production of the highest quality medical marijuana possible to provide relief to patients. The state-of-the-art facilities that we are developing are unique for the cannabis industry and I am honored to take on this role with the company.”
AmeriCann is developing a 53-acre property in Massachusetts (acquired from Boston Beer Company (SAM-NYSE) for $4,475,000 in cash), as the Massachusetts Medical Cannabis Center (the “MMCC”). The MMCC is approved for 1 million square feet and is expected to be one of the largest and most technologically advanced cannabis cultivation facilities in the nation. AmeriCann has plans to replicate the MMCC design in regulated markets across the United States.
About Dr. Brian Corr
With over forty years of experience in controlled-environment horticulture, Dr. Corr is a well-known and sought after expert in the scientific production of crops. Over his long career he has traveled to over 30 countries to provide horticultural advice. He will be Vice President of Operations for AmeriCann, responsible for facility design, operations, and product development.
Dr. Corr has earned three degrees including a PhD in plant sciences. He has worked both in industry and academia. As a faculty member at the University of Tennessee he specialized in controlled-environment horticulture. He has also worked for international firms specializing in plant genetics and crop protection. Over the course of his career he has managed a research greenhouse, had responsibility for international sales, was a director of new crop development, managed the commercial introduction of a product for certified-organic grape production, and directed numerous research projects related to crop production, including crop enhancement with beneficial microorganisms.
About AmeriCann
AmeriCann is a publicly traded Ag-Tech company that is developing and sustainable, state-of-the-art medical cannabis cultivation properties. The Company has over 1,000,000 square feet of facilities in the planning and design stages of development. The Company has designed a proprietary line of cannabis infused products which will be branded and licensed to companies in regulated markets.
AmeriCann, Inc. is a Certified B Corp, an acknowledgment of the company’s commitment to social and environmental ethics, transparency and accountability. AmeriCann became the first public cannabis company to earn this respected accreditation. More information about the Company is available at: www.americann.co or follow AmeriCann on Twitter @ACANinfo
About Massachusetts Medical Cannabis Center
The Massachusetts Medical Cannabis Center is approved for nearly 1,000,000 square feet of medical cannabis cultivation and processing in Freetown, Massachusetts. The state-of-the-art, sustainable, greenhouse project will consist of multiple planned phases for tenants in the Massachusetts medical marijuana market. AmeriCann’s Cannopy System uniquely combines expertise from traditional horticulture, lean manufacturing, regulatory compliance and cannabis cultivation to create superior facilities and procedures.
The first phase of the project consists of 130,000 sq. ft. of cultivation and processing infrastructure. AmeriCann can expand the first phase to approximately 600,000 sq. ft., based on patient demand.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended September 30, 2016, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.
Contact Information:
Corporate:
AmeriCann, Inc.
3200 Brighton Blvd. Unit 114
Denver, CO 80216
(303) 862-9000
info@americann.co
Investors:
Hayden IR
hart@haydenir.com
(917) 658-7878
